Rhone-Poulenc Rorer
Executive Summary
Company will pay over $1 mil. to the Canadian government under a "voluntary compliance undertaking" resulting from a December 1991-July 1992 investigation by the Canadian Patented Medicine Prices Review board of the price of the nonbenzodiazepine hypnotic Imovane. RPR surrendered patent rights to Imovane in Canada in July 1992. The company said it is not developing the product for the U.S.